Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: Evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 42-51

  Brown, Thomas E ^a   Landgraf, Jeanne M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HealthActCHQ Inc   (United States)

Author keywords

Attention deficit hyperactivity disorder; Executive function; Health related quality of life; Mixed amphetamine salts

Indexed keywords

AMPHETAMINE; PLACEBO; SPD 465; UNCLASSIFIED DRUG; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE;

ADHD IMPACT MODULE ADULT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BROWN ATTENTION DEFICIT DISORDER SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; EXECUTIVE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MENTAL FUNCTION; MENTAL PERFORMANCE; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADOLESCENT; ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; HUMANS; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE;

EID: 78049501841     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2200     Document Type: Article

References (25)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
2. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540.
3. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763.
4. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437-1448.
5. Spencer TJ, Adler LA, Weisler RH, Youcha SH, Anderson CS, Silverberg A. Efficacy and safety of a novel enhanced extended-release amphetamine formulation (triple-bead mixed amphetamine salts, SPD465) in adults with ADHD. Presented at: 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA.
6. Goodman DA, Spencer TJ, Adler LA, Weisler RH. Clinical evaluation of triple-bead mixed amphetamine salts in adult ADHD. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 23-28, 2007; Boston, MA.
7. Brown TE. Brown Attention-Deficit Disorder Scales for Adolescents and Adults. San Antonio, TX: The Psychological Corporation; Harcourt Assessment; 1996.
8. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord. 2007;11(3):351-362.
9. Baumeister R, Vohs K, eds. Handbook of Self-Regulation: Research, Theory and Applications. New York, NY: Guilford Press; 2004.
10. Brown TE. Attention Deficit Disorder: The Unfocused Mind in Children and Adults. New Haven, CT: Yale University Press; 2005.
11. Barkley RA. ADHD and the Nature of Self-Control. New York, NY: Guilford Press;1997.
12. Brown TE, Quinlan D. Assessing OROS methylphenidate effects on executive functions in adults with ADHD. Presented at: the Institute on Psychiatric Services Annual Meeting; October 2004; Atlanta, GA.
13. Brown TE, Sutton VK, Rogers AK, Sumner C. Atomoxetine alleviates executive function impairment associated with ADHD. Presented at: American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta, GA.
14. Childress A, Brams M, Gao J, Gasior M, Squires L, Brown TE. Lisdexamfetamine dimesylate improves executive function and duration of task output in adults with attention-deficit/hyperactivity disorder. Presented at: US Psychiatric and Mental Health Congress Conference and Exhibition; November 2-5, 2009; Las Vegas, NV.
15. Kooij JJ, Boonstra AM, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11(4):445-458.
16. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med. 2002;156(4):384-391.
17. Weiss MD, Gibbins C, Goodman DW, Hodgkins PS, Landgraf JM, Faraone SV. Moderators and mediators of ADHD and quality of life outcomes in adults treated for ADHD. J Clin Psychiatry. 2010;71(4):381-390.
18. Landgraf JL, Spencer TJ, Youcha SH, Anderson CS, Silverberg A, LeDay A. Evaluating quality of life in adults with ADHD following triple-bead mixed amphetamine salts (SPD465) treatment. Presented at: 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA.
19. Brams M, Giblin J, Gao J, Gasior M, Squires L, Wigal T. Effect of treatment with lisdexamfetamine dimesylate on self-reported quality of life in adults with attention-deficit/hyperactivity disorder. Presented at: US Psychiatric and Mental Health Congress Conference and Exhibition; November 2-5, 2009; Las Vegas, NV.
20. Dowdy S, Wearden S. Statistics for Research. New York, NY: John Wiley & Sons, Inc. 1983.
21. Makris N, Biederman J, Valera EM, et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/hyperactivity disorder. Cereb Cortex. 2007;17(16):1364-1375.
22. Brocki K, Fan J, Fossella J. Placing neuroanatomical models of executive function in a developmental context: imaging and imaging-genetic strategies. Ann N Y Acad Sci. 2008;1129:246-255.
23. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol. 2006;26(6):648-652.
24. Matza LS, Johnston JA, Faries DE, Malley KG, Brod M. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res. 2007;16(9):1511-1520.
25. Epstein JN, Langberg JM, Lichtenstein PK, Altaye M, Brinkman WB, House K, Stark LJ. Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med. 2010;164(2):160-165.